From November 15, 2015, to March 9, 2021, scientists conducted an open-label, phase 3 randomized clinical trial at 17 Spanish centers to assess the efficacy and safety of intraoperative HIPEC in patients with locally advanced colon cancer. The primary outcome was the 3-year locoregional control (LC) rate, which was defined as the proportion of patients who did not have peritoneal disease recurrence after adjusting for intention to treat. Patients included ranged in age from 18 to 75 years old and had been diagnosed with locally advanced primary colon cancer prior to surgery. They discovered that combining HIPEC with complete surgical resection for locally advanced colon cancer enhanced the 3-year LC rate compared to surgery alone, and they recommend that this strategy be evaluated for patients with locally advanced colorectal cancer.

Temporary suspension of endocrine medication to seek pregnancy did not give a higher short-term risk of breast cancer events, including distant recurrence, than the external control cohort among select women with previous hormone receptor-positive (HR+) early breast cancer. Further investigation is required to ensure long-term safety.

The recent acquisition of OneOncology by AmerisourceBergen Corporation and TPG Capital highlights the potential for private equity to support and grow community oncology care across the United States. Private equity firms are seeing opportunities in oncology, as they could help slow or reverse the trend of hospitals consolidating practices by providing significant funding needed upfront to start and operate a community oncology practice. With all the changing insurance relationships and the cost of doing business on a day-to-day basis, that’s a pretty risky proposition. But if private equity firms provide capital support, then it’s somebody else’s financial risk. OneOncology is a management services organization that partners with community oncology practices to provide resources that help institutions improve care and remain sustainable as the reimbursement environment changes. Its services provide “shelter in the storm,” especially with value-based care. Many practices are entering into reimbursement models in which they are taking on downside-risk, being part of OneOncology’s network allows them to spread and minimize potential financial loss. The uniqueness of this model is that it supports practices while keeping the operational decision-making at the practice-level independent. The recent acquisition of OneOncology is further proof that OneOncology’s mission is receiving greater support, and […]

A total of 246 patients were randomly allocated to one of two groups: adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer (combination group) or FTD-TPI alone (FTD-TPI group). The median overall survival in the combo group was 10.8 months and 7.5 months in the FTD-TPI group. The median progression-free survival in the combo group was 5.6 months and 2.4 months in the FTD-TPI group.

This article discusses some key infectious disease information that was released in 2022 but is unrelated to COVID-19. The literature was reviewed for sound new information relevant to internal medicine experts and subspecialists whose practice does not focus on infectious diseases. The publications mentioned are about diverse species in various patient populations.

Vabbing (look it up on TikTok) is the practice of putting one’s own vaginal fluid to the body in order to attract future mates or suitors. Researchers have yet to determine whether or not human pheromones exist or how they function. Vabbing can alter a user’s psychological state, improving their perceived attractiveness. According to experts, those willing to attempt vabbing may already be the type of people capable of meeting a relationship or sexual partner.